Abstract 1460P
Background
Gal-3 expression in tumours is associated with resistance to checkpoint inhibitors (CPIs). In a preclinical study, Gal-3 inhibitor GB1211 restored CPI-binding to their targets in the presence of Gal-3 (Mabbitt et al. J Clin Oncol 2022 ), and enhanced CPI effects in NSCLC mouse models (Vuong et al. Cancer Res. 2019). The GALLANT-1 study (NCT05240131) will assess whether GB1211 + atz (a CPI) increases anti-tumour effects in pts with NSCLC.
Methods
GALLANT-1 is a phase IB/IIA study of first line GB1211 + atz in pts with advanced/metastatic NSCLC. Part A is an open-label dose confirmation study of GB1211 200 mg or 100 mg twice daily (BID) + atz 1200 mg every 3 weeks; Part B is a 12-week, randomized double-blind study of the safety and efficacy of the GB1211 dose from Part A + atz vs placebo + atz. Following Part B, pts will continue into an open-label extension study until disease progression or unacceptable toxicity occur. Here we report data from the ongoing Part A.
Results
In the 200 mg cohort (n = 7), all pts had an adverse event (AE); most were mild (Grade [Gr] 1–2) and no serious AEs were deemed related to GB1211 alone. After 2 weeks of therapy, 2 severe (Gr 3–4) autoimmune skin rashes were observed: pemphigus deemed related to atz, and perivascular lymphocytic infiltration deemed related to GB1211 + atz; both responded to steroids. As per protocol, it was recommended that the study continue but with a reduced dose (100 mg BID) in new pts (n = 2); 9 AEs (all Gr 1–2) were reported in these 2 pts. Two partial responses, as assessed by investigators, have been seen: 1 confirmed (100 mg cohort; Week 6; time on therapy: 14 weeks) and 1 awaiting confirmation (200 mg cohort; Week 18; time on therapy: 23 weeks). Steady-state plasma exposure at 200 mg was consistent with pharmacokinetic (PK) simulations, predicting a 2-fold increase compared with healthy volunteers at 100 mg. GB1211 PK did not seem altered in pts with NSCLC vs healthy volunteers.
Conclusions
This is the first clinical study to show that combining GB1211 with atz may enhance the CPI effect. As the AEs have been manageable, Part A will continue with the 100 mg GB1211 dose to confirm the selected dose for Part B.
Clinical trial identification
NCT05240131.
Editorial acknowledgement
Third-party medical writing assistance was provided by Roisin Weaver MSc, of Ashfield MedComms, an Inizio company, and was funded by Galecto Biotech AB.
Legal entity responsible for the study
Galecto Biotech AB.
Funding
Galecto Biotech AB.
Disclosure
F.D.A. Aparisi Aparisi: Financial Interests, Personal, Advisory Role: Sanofi; Financial Interests, Personal, Speaker’s Bureau: Takeda; Financial Interests, Personal, Other, Travel, accommodations, expenses: Pfizer. E. Felip: Financial Interests, Personal, Advisory Board: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Gilead, GSK, Janssen, Merck Serono, Merck Sharp & Dohme, Novartis, Peptomyc, Regeneron, Sanofi, Takeda, Turning Point, Pfizer; Financial Interests, Personal, Invited Speaker: Amgen, Daiichi Sankyo, Genentech, Janssen, Medical Trends, Medscape, Merck Serono, PeerVoice, Pfizer, Sanofi, Takeda, Touch Oncology, AstraZeneca, Bristol Myers Squibb, Eli Lilly, F. Hoffmann-La Roche, Merck Sharp & Dohme; Financial Interests, Personal, Member of Board of Directors, Independent member: Grifols; Financial Interests, Institutional, Local PI, Clinical Trial: AstraZeneca AB, AbbVie, Amgen, Bayer Consumer Care AG, BeiGene, Boehringer Ingelheim GmbH, Bristol Myers Squibb International Corporation, Daiichi Sankyo Inc., Exelixis Inc., F. Hoffmann-La Roche Ltd., Genentech Inc., GSK Research and Development Limited, Janssen Cilag International NV, Merck Sharp & Dohme Corp, Merck KGAA, Mirati Therapeutics Inc, Novartis Pharmaceutica SA, Pfizer, Takeda Pharmaceuticals International; Non-Financial Interests, Leadership Role, President (2021-2023): SEOM (Sociedad Espanola de Oncologia Medica); Non-Financial Interests, Member, Member of Scientific Committee: ETOP (European Thoracic Oncology Platform); Non-Financial Interests, Member, Member of the Scientific Advisory Committee: CAC Hospital Universitari Parc Taulí. E. Pichon: Financial Interests, Institutional, Funding: BeiGene, Bristol Myers Squibb, MSD, Janssen, AstraZeneca; Financial Interests, Institutional, Other, Honoraria: Bristol Myers Squibb, AstraZeneca; Financial Interests, Personal, Other, Travel/Accommodation/Expenses, Honoraria: Takeda; Financial Interests, Personal, Advisory Board: Takeda. E. Carcereny: Financial Interests, Personal, Invited Speaker: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Pfizer, Roche, Takeda; Financial Interests, Personal, Advisory Role: AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, MSD, Novartis, Roche, Takeda; Financial Interests, Personal, Research Grant: Merk. R. Raumlau: Financial Interests, Personal, Advisory Board: Roche, Boehringer Ingelheim, Pfizer, MSD, BMS, Novartis, Takeda, Parexel; Financial Interests, Personal, Invited Speaker: Roche, Boehringer Ingelheim, Novartis, Pfizer, Amgen, BMS, MSD, Merck, AstraZeneca, Parexel, Bioatla Inc, Janssen-Cilag, AstraZeneca, Maia Biothechnology, Cantargia AB, Shanghai Henlius Biotech, BioNtech SE, Arcus Biosciences Inc. T. Sethi: Financial Interests, Personal, Stocks/Shares: Galecto Biotech, AstraZeneca; Financial Interests, Personal, Expert Testimony: Galecto Biotech; Financial Interests, Personal, Royalties: Galecto Biotech; Financial Interests, Personal, Advisory Role: Galecto Biotech; Financial Interests, Personal, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Other, Patents, other intellectual property: Galecto Biotech; Non-Financial Interests, Personal, Advisory Role: Affibody. B. Lindmark: Financial Interests, Personal, Stocks/Shares: Galecto Biotech, ALK-Abello, Aqilion AB; Financial Interests, Personal, Officer: Galecto Biotech; Financial Interests, Personal, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Member of Board of Directors: ALK-Abello, Aqilion AB; Financial Interests, Personal, Leadership Role: ALK-Abello. R. Slack: Financial Interests, Institutional, Stocks/Shares: Galecto Biotech; Financial Interests, Institutional, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Stocks/Shares: GSK. A. MacKinnon: Financial Interests, Personal and Institutional, Stocks/Shares: Galecto Biotech; Financial Interests, Personal and Institutional, Expert Testimony: Galecto Biotech; Financial Interests, Personal and Institutional, Royalties: Galecto Biotech; Financial Interests, Personal and Institutional, Funding: Galecto Biotech; Financial Interests, Personal and Institutional, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal and Institutional, Other, Patents, other intellectual property: Galecto Biotech. V. Aslanis: Financial Interests, Personal, Stocks/Shares: Galecto Biotech; Financial Interests, Personal, Funding: Galecto Biotech; Financial Interests, Personal, Full or part-time Employment: Galecto Biotech. D. Phung: Financial Interests, Personal, Stocks/Shares: Galecto Biotech; Financial Interests, Personal, Advisory Role: Galecto Biotech; Financial Interests, Personal, Full or part-time Employment: Galecto Biotech. P. Jensen: Financial Interests, Institutional, Stocks/Shares: Galecto Biotech; Financial Interests, Institutional, Advisory Role: Galecto Biotech; Financial Interests, Institutional, Full or part-time Employment: Galecto Biotech; Financial Interests, Institutional, Other, Travel, accommodation, expenses: Galecto Biotech. Z. Rajiwate: Financial Interests, Personal, Stocks/Shares: Galecto Biotech; Financial Interests, Personal, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Other, Travel, accommodations, expenses: Galecto Biotech. G. Ross: Financial Interests, Institutional, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Stocks/Shares: Roche/Genentech, GSK, AstraZeneca; Financial Interests, Personal, Full or part-time Employment: Graham Ross Oncology Consulting Services Ltd, Various (in my capacity as freelance physician); Financial Interests, Personal, Advisory Role: Various (in my capacity as freelance physician); Financial Interests, Personal, Leadership Role: Various (in my capacity as freelance physician); Financial Interests, Personal, Other, Travel, Accommodation, Expenses: Various (in my capacity as freelance physician). L. Basse: Financial Interests, Personal, Full or part-time Employment: Galecto Biotech; Financial Interests, Personal, Stocks/Shares: Genmab, NovoNordisk, Lava Therapeutics, Ambu, BioNTech; Financial Interests, Personal, Advisory Role: Ambu; Financial Interests, Personal and Institutional, Full or part-time Employment: ClinPharmaResearch; Financial Interests, Personal and Institutional, Ownership Interest: ClinPharmaResearch. F. Ghiringhelli: Financial Interests, Institutional, Funding: AstraZeneca/MedImmune; Financial Interests, Personal, Other, Honoraria, Travel, Accommodation, Expenses: Roche/Genentech; Financial Interests, Personal, Other, Travel, Accommodation, Expenses: Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
1432P - Tumor stage shift in lung cancer during the COVID-19 pandemic: A real-world data study of the Network Oncology Registry
Presenter: Anja Thronicke
Session: Poster session 20
1433P - CNS efficacy of atezolizumab, bevacizumab, carboplatin and paclitaxel in patients with non-small cell lung cancer and actionable mutations
Presenter: Marcus Rathbone
Session: Poster session 20
1434P - Machine learning features derived from spatial interaction of immune cell families are associated with survival in NSCLC patients post-immunotherapy
Presenter: sara arabyarmohammadi
Session: Poster session 20
1435P - Clinical and molecular study with digital support of advanced non-small cell lung cancer patients: SNF-CLIMEDIN, a prospective randomized Hellenic Cooperative Oncology Group (HeCOG) study: Interim analysis
Presenter: Helena Linardou
Session: Poster session 20
1436P - Prospective study utilizing ctDNA genome-wide copy number variations for longitudinal monitoring of patients with advanced non-small cell lung cancer
Presenter: Pengkai Han
Session: Poster session 20
1437P - Clinical and economic burden of tissue re-biopsy (TRB) vs. tissue followed by liquid biopsy (TFLB) in metastatic non-small cell lung cancer (mNSCLC) patients
Presenter: Nicole Engel-Nitz
Session: Poster session 20
1438P - Cemiplimab for advanced non-small cell lung cancer: Squamous subgroup analysis for EMPOWER-Lung 1 and 3
Presenter: Tamta Makharadze
Session: Poster session 20
1440P - Final top-line results of the BGBC008 phase II, multicenter study of bemcentinib and pembrolizumab (bem+pembro) in second-line (2L) advanced non-squamous (NS) non-small cell lung cancer (NSCLC) (NCT03184571)
Presenter: Enriqueta Felip
Session: Poster session 20
1441P - Atezolizumab and bevacizumab (atezo + bev) ± radiotherapy (RT) vs docetaxel (doc) in checkpoint inhibitor (CPI)–experienced metastatic NSCLC (mNSCLC): Results from the phase Ib/II MORPHEUS-lung study
Presenter: Francois Ghiringhelli
Session: Poster session 20